Price T Rowe Associates Inc Spring Works Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,582,732 shares of SWTX stock, worth $120 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,582,732
Previous 3,274,786
21.13%
Holding current value
$120 Million
Previous $118 Million
3.67%
% of portfolio
0.01%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding SWTX
# of Institutions
361Shares Held
63.1MCall Options Held
5.81MPut Options Held
2.55M-
Vanguard Group Inc Valley Forge, PA7.08MShares$328 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$260 Million0.0% of portfolio
-
State Street Corp Boston, MA2.92MShares$135 Million0.01% of portfolio
-
Woodline Partners LP San Francisco, CA2.14MShares$99.3 Million0.66% of portfolio
-
Polar Capital Holdings PLC London, X01.75MShares$81 Million0.52% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $2.89B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...